Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human IL-13 Protein, His Tag, premium grade, 50 µg  

Recombinant Human IL-13 Protein, His Tag, premium grade, 50 µg

Recombinant Human IL-13 Protein, expressed from human HEK293 cells, contains AA Gly 21 - Asn 132, His Tag, premium grade

Synonym
recombinant, human, protein, IL13, ALRH, BHR1, MGC116786, MGC116788, MGC116789, P600, Interleukin-13

More details

IL3-H52H4-50

Availability: within 7 days

507,00 €

Background
Interleukin 13 (IL13) is also known as ALRH, BHR1and P600, is a single-chain glycosylated polypeptide, and is a cytokine critical in regulating inflammatory and immune responses. IL13 is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 induces its effects through a multi-subunit receptor that includes the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains. The functions of IL-13 overlap considerably with those of IL-4, especially with regard to changes induced on hematopoietic cells, but these effects are probably less important given the more potent role of IL-4. IL-13 induces matrix metalloproteinases (MMPs) as part of a mechanism that protects against excessive allergic inflammation that predisposes to asphyxiation. IL-13 induces many features of allergic lung disease, including airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion, which all contribute to airway obstruction.

Source
Recombinant Human IL-13, His Tag, premium grade(IL3-H52H4) is expressed from human 293 cells (HEK293). It contains AA Gly 21 - Asn 132 (Accession # AAK53823.1).
Predicted N-terminus: Gly 21
Human IL-13 Protein, His Tag, premium grade (IL3-H52H4), designed for preclinical stage, has the same activity and performance with GMP Human IL-13 Protein, which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 14.2 kDa. The protein migrates as 15 kDa and 25-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Sterility
The sterility testing was performed by membrane filtration method.

Mycoplasma
Negative.
 
Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "GPR120/FFAR4 stimulation attenuates airway remodeling and suppresses IL-4- and IL-13-induced airway epithelial injury via inhibition of STAT6 and Akt"
Moonwiriyakit, Yimnual, Noitem et al
Biomed Pharmacother (2023) 168, 115774
(2) "Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas"
Kim, Kim, Park et al
Melanoma Res (2023)
(3) "Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review"
Blauvelt, Langley, Gordon et al
Dermatol Ther (Heidelb) (2023)
Showing 1-3 of 17086 papers.